FindTrial
Sign In

Clinical research on the cell stromal determined by multimodal ultrasound imaging technology in warning of endocrine resistance for breast cancer

Clinical research on the cell stromal determined by multimodal ultrasound imaging technology in warning of endocrine resistance for breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036818
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Clinical outcome
Index test:Determine&#32
cell&#32
stromal&#32
by&#32
multimodal&#32
ultrasound&#32
imaging&#32
technology

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Signed informed consent; 2. ER+ subtype breast cancer patients who were sensitive or resistant to endocrine therapy in our hospital from 2016 to 2020; 3. Patients with complete clinical and multimodal ultrasound imaging information.

Exclusion criteria

Exclusion criteria: 1. Contraindication of CEUS; 2. Patients without complete clinical information; 3. Patients without complete multimodal ultrasound imaging information.

Design outcomes

Primary

MeasureTime frame
Resistance Time;Clinical Staging of Tumor;Pathological Grade;Estrogen Receptor;Progesterone Receptor;Ki-67;Her-2;Collagen Content;Morphology;Boundary;Elasticity Mean;Elasticity Max;Arrival Time;Peak Intensity;—

Countries

China

Contacts

Public ContactMin Bai

Shanghai General Hospital

baimin101@126.com+86 13917045725

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026